ACHN News and Press, Achison Inc Cl A From 12/10/18

NEW HAVEN, Conn., Dec. 10, 2018 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company focused on advancing its orally administered factor D complement inhibitors into late-stage development and commercialization, announced...

Achillion Pharmaceuticals (NASDAQ: ACHN ): Q3 GAAP EPS of -$0.12  beats by $0.02 . More news on: Achillion Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

- Completed enrollment of Phase 2 clinical trial of ACH-4471 in PNH as monotherapy - - Interim data and strategic update planned for December 17, 2018 – - September 30, 2018 cash & securities position of $283 million –  - Mary Kay Fenton to step down as CFO at ...

NEW YORK, Oct. 17, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of SunOpta, Inc. (NASDAQ:STKL), Acorda Therapeutics, Inc. (NASDAQ:ACOR), Sap...

Results from a Phase 1b assessing the pharmacokinetics of Ra Pharmaceuticals' (NASDAQ: RARX ) RA101495 SC (zilucoplan) in patients with severe renal impairment showed a similar profile compared to healthy patients. There were no adverse events reported and the data indicate that no adjust...

NEW HAVEN, Conn., Sept. 25, 2018 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) announced today that Joseph Truitt, President and Chief Executive Officer of Achillion, will present at the Leerink Partners Roundtable Series: Rare Disease & Oncology on Tuesday, Octob...